Evidence map›Paper›PMID 32528293›Full record

ArticleFrontiers in pharmacology2020

Corrigendum: The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners.

Francisco Esteves, Diana Campelo, Bruno Costa Gomes, Philippe Urban, Sophie Bozonnet, Thomas Lautier, José Rueff, Gilles Truan, Michel Kranendonk

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Francisco EstevesCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal.
Diana CampeloCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal.
Bruno Costa GomesCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal.
Philippe UrbanCentre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France.
Sophie BozonnetCentre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France.
Thomas LautierCentre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France.
José RueffCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal.
Gilles TruanCentre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France.
Michel KranendonkCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2020.00299.].

Indexed as

binding motifscytochrome P450 monooxygenases (CYP)electron transferFMN-domainNADPH cytochrome P450 oxidoreductase (CPR)protein–protein interactionredox partner

Identifiers

PMID32528293
PMCPMC7253713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.